Novavax to Move Forward With Covid-19-Flu Vaccine

FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
US FDA lifts clinical hold on Novavax's combo COVID-flu shot
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated to the combination shot,
FDA Lifts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Up
(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. Novavax shares were up more than 13 percent in pre-market.
Novavax, Inc.: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax can move forward with a trial for its combined Covid-19 and influenza vaccine after regulators lifted a clinical hold. The Gaithersburg, Md., vaccine developer said Monday that the U.S. Food and Drug Administration had removed the clinical hold on its investigational new drug application for its combined vaccine and its standalone flu vaccine candidates.
Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot
The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY).
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials
Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.
Yahoo Finance4h
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that Novavax ...
BioPharma Dive51m
FDA lifts pause on Novavax flu vaccine trials
The agency authorized Novavax to start a Phase 3 trial of its combination shot after the company “satisfactorily” ...
Nasdaq25d
Novavax (NASDAQ:NVAX) Stock Drops 18% after Clinical Trial Is Halted
Shares of pharmaceutical company Novavax (NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has halted one of the company’s clinical trials over safety concerns.
pharmaphorum23d
Novavax is latest biotech to begin coronavirus vaccine trial
Maryland-based Novavax said it had enrolled the first participants in a phase 1/2 clinical trial of its coronavirus vaccine candidate. The vaccine, NVX-CoV2373, is a stable, prefusion protein ...
FiercePharma5d
Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
MarketWatch26d
Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates
Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold ... participant in a mid-stage trial. Motor neuropathy is ...
Hosted on MSN6d
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to ...